Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating
On February 4, 2026, Barclays raised its price target on CytomX Therapeutics, Inc.
Cytomx Therapeutics Inc. (CTMX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 9,680,185 | $41,237,588 | 0.74% | |
| 2. | Kynam Capital Derrick Tang | 8,966,077 | $38,195,488 | +146% | 2.44% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 7,692,300 | $32,769,198 | 2.18% | |
| 4. | Point72 Asset Management Steve Cohen | 5,189,538 | $22,107,432 | +28% | 0.02% |
| 5. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,250,826 | $18,108,519 | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.55 | 5,000 | $7,750.00 | 5,142 | 2023-03-29 | Filing | |
| $10.33 | 9,000 | $92,970.00 | 9,979 | 2019-03-04 | Filing | |
| $12.00 | 3,000 | $36,000.00 | 3,000 | 2015-10-14 | Filing | |
| $12.00 | 5,000 | $60,000.00 | 5,000 | 2015-10-14 | Filing | |
| $12.00 | 5,000 | $60,000.00 | 5,000 | 2015-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.54 | 101,793 | $461,906.10 | 987,891 | 2025-11-06 | Filing | |
| $2.69 | 10,614 | $28,539.98 | 226,271 | 2025-06-16 | Filing | |
| $2.95 | 1,641 | $4,841.44 | 199,385 | 2025-06-13 | Filing | |
| $2.69 | 13,884 | $37,334.08 | 272,252 | 2025-06-16 | Filing | |
| $2.69 | 55,511 | $149,263.53 | 1,089,684 | 2025-06-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,688,109 | $105,171,344 | 0.01% | |
| 2. | 15,561,500 | $66,291,990 | 3.27% | |
| 3. | 8,475,584 | $36,105,988 | 0% | |
| 4. | 5,140,931 | $21,900,366 | 0% | |
| 5. | 3,828,717 | $16,310,334 | 0.03% |
News See All
15 Best Small Cap Stocks to Buy According to Wall Street
Small-cap stocks are beginning to draw renewed attention in 2026 as investors reassess where the next leg of returns could come from.
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)
TheFly reported on January 20 that Piper Sandler raised its price target on CTMX to $10 from $6.50, keeping an Overweight rating. The firm noted that Initial Phase 1 data for varsetatug maseatecan...
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
10 Best US Penny Stocks to Buy
On December 23, CNBC reported that Julie Biel, Chief Market Strategist at Kayne Anderson Rudnick, joined Fast Money to discuss where the Russell 2000 may be headed and what investors can expect from small...
Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress
On December 5, 2025, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw H.C.
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
CX-2051 Momentum and An Expanding Oncology Pipeline Strengthen CytomX Therapeutics’ (CTMX) Investment Case
The Fly reported on November 11, 2025, that CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s price target was raised from $5 to $10 by H.C. Wainwright’s Mitchell Kapoor.
12 Hot Penny Stocks to Invest in Right Now
Goldman Sachs Asset Management portfolio manager Greg Tuorto appeared on CNBC on November 17, 2025.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2025 Financial Results Call. Please be advised that today's call is being recorded.
Hedge Fund Resource Center